176 related articles for article (PubMed ID: 38604287)
1. Precision nanomedicine to treat non-small cell lung cancer.
Dessai A; Nayak UY; Nayak Y
Life Sci; 2024 Jun; 346():122614. PubMed ID: 38604287
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicine for Treatment of Lung Cancer.
Hussain S
Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803
[TBL] [Abstract][Full Text] [Related]
3. NSCLC as the Paradigm of Precision Medicine at Its Finest: The Rise of New Druggable Molecular Targets for Advanced Disease.
Michelotti A; de Scordilli M; Bertoli E; De Carlo E; Del Conte A; Bearz A
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743191
[TBL] [Abstract][Full Text] [Related]
4. Near-infrared/pH dual-responsive nanocomplexes for targeted imaging and chemo/gene/photothermal tri-therapies of non-small cell lung cancer.
Li Z; Zhu L; Liu W; Zheng Y; Li X; Ye J; Li B; Chen H; Gao Y
Acta Biomater; 2020 Apr; 107():242-259. PubMed ID: 32151700
[TBL] [Abstract][Full Text] [Related]
5. Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Halliday PR; Blakely CM; Bivona TG
Curr Oncol Rep; 2019 Feb; 21(3):21. PubMed ID: 30806814
[TBL] [Abstract][Full Text] [Related]
6. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
7. Cationic lipid-assisted polymeric nanoparticle mediated GATA2 siRNA delivery for synthetic lethal therapy of KRAS mutant non-small-cell lung carcinoma.
Shen S; Mao CQ; Yang XZ; Du XJ; Liu Y; Zhu YH; Wang J
Mol Pharm; 2014 Aug; 11(8):2612-22. PubMed ID: 24521262
[TBL] [Abstract][Full Text] [Related]
8. Applications and strategies in nanodiagnosis and nanotherapy in lung cancer.
Woodman C; Vundu G; George A; Wilson CM
Semin Cancer Biol; 2021 Feb; 69():349-364. PubMed ID: 32088362
[TBL] [Abstract][Full Text] [Related]
9. Precision medicine in ALK rearranged NSCLC: A rapidly evolving scenario.
Addeo A; Tabbò F; Robinson T; Buffoni L; Novello S
Crit Rev Oncol Hematol; 2018 Feb; 122():150-156. PubMed ID: 29458783
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Roberts PJ; Stinchcombe TE; Der CJ; Socinski MA
J Clin Oncol; 2010 Nov; 28(31):4769-77. PubMed ID: 20921461
[TBL] [Abstract][Full Text] [Related]
11. [Personalized therapy of lung cancer - current standard and future challenges].
Riedel R; Wolf J
Dtsch Med Wochenschr; 2017 Nov; 142(22):1660-1668. PubMed ID: 29078211
[TBL] [Abstract][Full Text] [Related]
12. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
13. Synthetic Lethality: From Research to Precision Cancer Nanomedicine.
Gupta A; Ahmad A; Dar AI; Khan R
Curr Cancer Drug Targets; 2018; 18(4):337-346. PubMed ID: 28669337
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine-based neuroprotective strategies in patient specific-iPSC and personalized medicine.
Jang SF; Liu WH; Song WS; Chiang KL; Ma HI; Kao CL; Chen MT
Int J Mol Sci; 2014 Mar; 15(3):3904-25. PubMed ID: 24599081
[TBL] [Abstract][Full Text] [Related]
15. [Targeted therapy and precision medicine : More than just words in the treatment of lung cancer].
Heigener DF; Horn M; Reck M
Internist (Berl); 2016 Dec; 57(12):1243-1249. PubMed ID: 27587193
[TBL] [Abstract][Full Text] [Related]
16. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
Shea M; Costa DB; Rangachari D
Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
[TBL] [Abstract][Full Text] [Related]
17. Precision Nanomedicine Development Based on Specific Opsonization of Human Cancer Patient-Personalized Protein Coronas.
Ren J; Cai R; Wang J; Daniyal M; Baimanov D; Liu Y; Yin D; Liu Y; Miao Q; Zhao Y; Chen C
Nano Lett; 2019 Jul; 19(7):4692-4701. PubMed ID: 31244235
[TBL] [Abstract][Full Text] [Related]
18. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
19. Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Christofyllakis K; Monteiro AR; Cetin O; Kos IA; Greystoke A; Luciani A
J Geriatr Oncol; 2022 Nov; 13(8):1071-1083. PubMed ID: 35525790
[TBL] [Abstract][Full Text] [Related]
20. Personalized targeted therapy for lung cancer.
Wu K; House L; Liu W; Cho WCS
Int J Mol Sci; 2012; 13(9):11471-11496. PubMed ID: 23109866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]